Highly Active Antiretroviral Therapy and Sexual Risk Behavior
Top Cited Papers
- 14 July 2004
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 292 (2), 224-236
- https://doi.org/10.1001/jama.292.2.224
Abstract
Review from JAMA — Highly Active Antiretroviral Therapy and Sexual Risk Behavior — A Meta-analytic Review — ContextEvidence suggests that since highly active antiretroviral therapy (HAART) became available, the prevalence of unprotected sex and the incidence of sexually transmitted infections (STIs) have increased.ObjectiveTo conduct 3 meta-analyses to determine whether (1) being treated with HAART, (2) having an undetectable viral load, or (3) holding specific beliefs about HAART and viral load are associated with increased likelihood of engaging in unprotected sex.Data SourcesA comprehensive search included electronic bibliographic databases, including AIDSLINE, MEDLINE, PubMed, CINHAL, PsycInfo, ERIC, EMBASE, and Sociofile, from January 1996 to August 2003, conference proceedings, hand searches of journals, reference lists of articles, and contacts with researchers.Study SelectionTwenty-five English-language studies (some contributing >1 finding) met the selection criteria and examined the association of unprotected sexual intercourse or STIs with receiving HAART (21 findings), having an undetectable viral load (13 findings), or beliefs about HAART and viral load (18 findings).Data ExtractionReports were screened and information from eligible studies was abstracted independently by pairs of reviewers using a standardized spreadsheet.Data SynthesisRandom-effects models were used to aggregate data. The prevalence of unprotected sex was not higher among persons with the human immunodeficiency virus (HIV) receiving HAART (prevalence range, 9%-56%; median, 33%) vs those not receiving HAART (range, 11%-77%; median, 44%; odds ratio [OR], 0.92; 95% confidence interval [CI], 0.65-1.31) or among HIV-positive persons with an undetectable viral load (range, 10%-68%; median, 39%) vs those with a detectable viral load (range, 14%-70%; median, 42%; OR, 0.99; 95% CI, 0.82-1.21). The prevalence of unprotected sex was elevated (OR, 1.82; 95% CI, 1.52-2.17) in HIV-positive, HIV-negative, and unknown serostatus persons who believed that receiving HAART or having an undetectable viral load protects against transmitting HIV or who had reduced concerns about engaging in unsafe sex given the availability of HAART (range, 17%-81% [median, 49%] vs 9%-68% [median, 38%] for counterparts).ConclusionsIn the studies reviewed, HIV-positive patients receiving HAART did not exhibit increased sexual risk behavior, even when therapy achieved an undetectable viral load. However, people's beliefs about HAART and viral load may promote unprotected sex and may be amenable to change through prevention messages.Keywords
All Related Versions
This publication has 34 references indexed in Scilit:
- Impact of Highly Active Antiretroviral Treatment on HIV Seroincidence Among Men Who Have Sex With Men: San FranciscoAmerican Journal of Public Health, 2002
- Extent of Human Immunodeficiency Virus Type 1 Drug Resistance as a Predictor of Virological Failure after Genotype‐Guided Treatment SwitchClinical Infectious Diseases, 2001
- Are we headed for a resurgence of the HIV epidemic among men who have sex with men?American Journal of Public Health, 2001
- Increase in sexually transmitted infections among homosexual men in Amsterdam in relation to HAARTSexually Transmitted Infections, 2001
- Viral Load and Heterosexual Transmission of Human Immunodeficiency Virus Type 1New England Journal of Medicine, 2000
- Human Immunodeficiency Virus Type 1 in the Semen of Men Receiving Highly Active Antiretroviral TherapyNew England Journal of Medicine, 1998
- Changing patterns of mortality across Europe in patients infected with HIV-1The Lancet, 1998
- Public Health Implications of Antiretroviral Therapy and HIV Drug ResistanceJAMA, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected PatientsJAMA, 1998